



SAGA

PROCEEDINGS BOOK

DUTCH FOUNDATION
FOR POSTGRADUATE MEDICAL COURSES
IN INDONESIA 2019

THE CONTINUUM OF CARE IN PRE ECLAMPSIA MOTHER INFANT CHILD

UNIVERSITAS AIRLANGGA
FACULTY OF MEDICINE
Surabaya, April 8th - 9th 2019

**THE CONTINUUM OF CARE
IN PRE ECLAMPSIA MOTHER INFANT CHILD**

Penulis:

Agus Harianto, dr., SpA(K)

Divisi Neonatologi

Dr. Risa Etika, dr., SpA(K)

Divisi Neonatologi

Dr. Ahmad Suryawan, dr., SpA(K)

Divisi Tumbuh Kembang Pediatri Sosial

Prof. Dr. Erry Gumilar, dr., SpOG(K)

Divisi Fetomaternal

Dr. Ernawati Darmawan, dr., SpOG(K)

Divisi Fetomaternal

Muhammad Aldika Akbar, dr., SpOG(K)

Divisi Fetomaternal

Dr. S.M. Mei Wulan, dr., SpKFR(K)

Divisi Pediatri

Cetakan I: April 2019

ISBN: 978-602-5758-55-3

ISBN 978-602-5758-55-3



Penerbit

CV Saga Jawadwipa

PUSTAKA SAGA

Jl. Kedinding Lor, Gg. Delima, no 4A. Kenjeran, Surabaya
Email: saga.penerbit@gmail.com, HP: +62 856 5539 6657

Hak cipta dilindungi oleh undang-undang.
Dilarang memperbanyak sebagian atau seluruh
isi buku ini tanpa izin tertulis dari penerbit

DAFTAR ISI

KATA PENGANTAR | III

DUTCH FOUNDATION FOR POSTGRADUATE
MEDICAL COURSES IN INDONESIA | V

SUSUNAN PANITIA |VII

DAFTAR PEMBICARA | X

DAFTAR PENULIS | XII

DAFTAR ISI | XIII

1. *Peripartum Cardiomyopathy Related To Preeclampsia : Significant Overlap Between These Pregnancy Developing Complications* | 1
Erry Gumilar D
2. *Expectant Management of preterm preeclampsia in developing country, maternal outcomes, and perinatal survival* | 14
Ernawati
3. *The Hypertension in Pregnancy Problems in Indonesia* | 26
Muhammad Ilham Aldika Akbar
4. *Neonatal Respiratory Outcome in pregnancy induced hypertension* | 35
Agus Harianto

5. *Prevention and Management IUGR as
Complication of Pregnancy Induced
Hypertension* | 61
Risa Etika
6. *Long-term Developmental Outcome in Preterm
Infants born with Preeclampsia* | 87
Ahmad Suryawan
7. *The Role of Physical Medicine and
Rehabilitation in Improving Neonatal
Respiratory Outcome* | 95
S.M. Mei Wulan

Neonatal Respiratory Outcome in Pregnancy-Induced Hypertension

*Agus Harianto, Risa Etika, Martono Tri Utomo,
Dina Angelika, Kartika D Handayani, Mahendra Tri
Arif Sampurna.*

*Division of Neonatology, Department of Child Health,
Faculty of Medicine,
Universitas Airlangga, Surabaya.*

Abstract

Pregnancy-induced hypertension (PIH) is the most common medical complications in pregnancy globally and becomes one main cause of maternal morbidity and mortality. The classification of PIH are gestational hypertension, chronic hypertension, preeclampsia (PE), and pre-eclampsia superimposed on chronic hypertension. Based on literature, gestational hypertension and pre-eclampsia are the leading causes of maternal and perinatal mortality and morbidity. However, all types of PIH has less favorable outcome compared to newborns with normotensive mothers.

All newborns from mothers with PIH has higher prematurity rates, lower birthweight and longer hospital stay. Since PIH, especially preeclampsia, is a progressive disorder, delivery of fetus and placenta is the treatment of choice, especially when the gestational age greater than 34

weeks to terminate the progression. Even though, some studies showed contradictory results regarding respiratory outcome of newborns from hypertensive mothers less than 34 weeks of gestational age. Obstetricians should make sure that the benefits of terminating the pregnancy outweighs the risks including the maturity of newborns' respiratory system. On the other hand, it is important for neonatologists to understand the neonatal outcome of mothers with PIH especially the respiratory outcome. Since PE has high incidence and has less favorable outcome especially respiratory disorders, this article will focus in PE and neonatal respiratory outcomes.

The most recent cohort study showed that having pre-eclampsia mother is independently associated with higher risk for severe respiratory distress syndrome (RDS) and Bronchopulmonary Dysplasia (BPD). A theory states preeclampsia may cause acceleration in fetal lung maturation and will reduce the risk of RDS, but in the other hand, some studies suggested that PE may not accelerate lung maturity. Several studies examined the relationship between intrauterine exposure to maternal PE and the risk of the infant developing BPD. Some of these report that PE is protective and reduces the incidence of BPD. Others report that PE is associated with an increased incidence of BPD. Still others have found no change.

Pregnancy induce hypertension especially PE has less favorable outcomes mainly respiratory problems in neonates such as RDS and BPD. Proper resuscitation and intervention should be prepared in this matters. Multidisciplinary and collaborative approach between the field of maternal-fetal medicine and neonatology is necessary to optimize maternal and neonatal management of mothers who have PE.

Keywords : Pregnancy-Induced Hypertension, Preeclampsia , Respiratory Distress Syndrome, Bronchopulmonary Dysplasia

Introduction

Pregnancy-induced hypertension (PIH) which currently complicates around 10% pregnancy globally¹ is the most common medical complications in pregnancy². In Indonesia, the prevalence of PIH is around 12.7% and becomes one main causes of maternal morbidity and mortality³. Furthermore, in a higher income country such as United States, it affects between 6-8 % of all pregnancies⁴.

The classification of PIH based on National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy (2000) are gestational hypertension, chronic hypertension, preeclampsia (PE), and PE superimposed on chronic hypertension. Each type of PIH has different fetal and

neonatal outcome.⁵ Based on literature, gestational hypertension and PE are the leading causes of maternal and perinatal mortality and morbidity. Majority of maternal and perinatal deaths occurred in Low and Middle Income Countries (LMICs), while High Income Countries (HICs) have relatively low maternal and perinatal mortality ratio.²

A study conducted by Tachiwenyika et al, stated that PIH increased the risk of perinatal mortality ⁶. Another study also supported this finding by stating that women with hypertensive disorders of pregnancy have higher perinatal mortality ratio ⁷. In that study also revealed that risk factors of higher perinatal mortality are gestational age, parity, type and onset of hypertension, birth weight, mode of delivery, and maternal outcome.

According to our perspective, there are theories stated the definitive cure of PE is to end the pregnancy and deliver the baby. However, there is no clear guideline addressing the optimal timing for delivery. Furthermore, its significant effects on pregnancy outcome have become obstetricians' consideration in terminating pregnancy. Obstetricians should make sure that the benefits of terminating the pregnancy outweigh the risks including the maturity of newborns' respiratory system. On the other hand, it is important for neonatologists to understand the respiratory outcome of newborns from mothers with PIH. At this

point, neonatologists have important roles to prevent perinatal morbidity and mortality by providing early life treatment based on known PIH risk factor. There is also the need for multidisciplinary and collaborative approach between the field of maternal-fetal medicine and neonatology to optimize maternal and neonatal management of mothers who have PE. Therefore, this paper aims to discuss the Neonatal Respiratory Outcome in Pregnancy-Induced Hypertension.

Classification of Hypertensive Disorders of Pregnancy

It is important to understand types of PIH because each type has different pathogenesis and possibly management. Each type of PIH also has its own diagnostic criteria.

Table 1. Classification of Pregnancy-Induced Hypertension ⁸

| Category | Diagnostic Criteria |
|---|--|
| Chronic hypertension | Hypertension manifested before pregnancy, before 20 weeks of gestation, or persisting more than 12 weeks postpartum. |
| Gestational hypertension | Hypertension manifested after 20 weeks of gestation. |
| Preeclampsia | Development of hypertension after 20 weeks of gestation, associated with proteinuria (≥ 0.3 g in a 24-hour urine specimen or $\geq 1+$ on dipstick in two urine samples) in previously normotensive women. |
| Preeclampsia superimposed on chronic hypertension | Preeclampsia diagnosed in previously hypertensive women. |

From National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy 2000.

The gestational week of the first manifestation of hypertension is crucial in diagnosing PIH.




Figure 1. Incidence and classification of hypertensive disorders in pregnancy.

Roberts CL et al. Hypertensive disorders in pregnancy: a population based study. *MJA*. 2005;182:332-335

Currently, PIH accounts for almost 10% of all pregnancies worldwide. PIH itself are divided by several classifications. Gestational hypertension is the leading type of PIH. Followed by with PE which only have 1% incidence difference compared to gestational hypertension. Due to its substantial

percentage and complex pathogenesis, the later part of this paper will focus on PE.

PE is a great challenge for obstetricians due to its unknown cause, its pathophysiology is complex and incompletely understood, its diagnosis may be difficult to determine, there's still no effective treatments, and antenatal care involves a difficult balance between the risks for women to continue pregnancy and those for the baby's early birth.

Patophysiology of Preeclampsia

Definite cause of PE still remains unknown, but immune and vascular matters have been involved in its pathogenesis. PE considerably have two-stage disease (figure 2), the placental effects and systemic effects. The combination of imbalance of angiogenic factors and oxidative stress plays role in this pathophysiology.¹⁰

In a mouse model study, it showed that less favorable outcome was found among fetuses and infants from mothers with early PE, it is because PE is a placental disease and late PE is a maternal systemic disease¹¹




Figure 2. Pathogenesis of PE.

de Souza Rugolo L et. al. PE: Effect on the Fetus and Newborn. *Neoreviews*. 2011;12(4):e198-e206.

In addition, placental oxidative stress is considered as an intermediate event in PE pathogenesis. Some studies showed that oxidative stress plays role in endothelial dysfunction and lead to PE.^{12,13,14}

Evidence suggests that angiogenic factors also play role in PE pathophysiology. Imbalance of angiogenic-antiangiogenic factors might affect pregnancy outcome such as observed in PE and Intra Uterine Growth Restriction (IUGR) condition. Placental angiogenesis is regulated by many growth

factors, however vascular endothelial growth factor (VEGF) is involved in this critical step. A subtype of VEGF, placental growth factor (PlGF), enhances the VEGF response itself.¹⁵ Antiangiogenic factors which consist of soluble form of endoglin (sEng) and tyrosine kinase (sFlt1) are increased in PE and have role in PE complications. However, the mechanisms by which angiogenic factors play role in PE remains unclear.^{15,16}

Recently, epigenetic factors have been considered to play role in PE pathogenesis, although it still remains unclear.^{17,18} Recent experimental studies have been conducted to discover new insights into PE pathophysiology. It was found that disturbed regulation in genes expression considerably plays role in pathogenesis of placental insufficiency.¹⁸ Those complex mechanisms of PE are not fully understood and still remain unclear.

Outcome

Regardless of types of PIH, it has less favorable outcome compared to newborns with normotensive mothers. All newborns from mothers with PIH has higher prematurity rates, lower birthweight and longer hospital stay¹⁹.

One of types of PIH, PE is a progressive disorder and delivery of fetus and placenta is the treatment of choice especially when the gestational

age greater than 34 weeks to terminate the progression^{20,21,22}. However, premature delivery has adverse effects on neonatal outcomes²².




Figure 3. Perinatal Mortality in PE according to Gestational Age

Haddad B et al. Expectant management in pregnancies with severe pre-eclampsia.

Semin Perinatol. 2009;33:143-151

Several studies showed the rates of all preterm and late preterm deliveries in healthy nulliparous women with mild PE. Hauth et al found only 1,9% infants born before 34 weeks of gestation, 10,6% infants born between 34 weeks until 37 weeks, and in total there was 12,5% infants born prior to 37 weeks. In addition, there was study that

showed similar results. Hnat et al found only 2,3% infants born before 34 weeks of gestation, 11,7% infants born between 34 weeks until 37 weeks, and in total there was 14% infants born prior to 37 weeks. Those results implied that the rates of preterm and late preterm infants were very low in healthy nulliparous women with mild PE.^{24,25}

Table 2. Neonatal Complication in Pregnancies involving PE

| Problem | Comments |
|--|--|
| Respiratory Distress Syndrome | No difference in incidence; lung maturity is not accelerated in PE. |
| Thrombocytopenia | Associated with low birthweight and prematurity; early manifestation and transient course |
| Neutropenia | High incidence in the first 72 hours after birth and may be associated with increased risk of infection |
| Necrotizing Enterocolitis | Increased risk, primarily newborns who have intrauterine growth restriction. |
| Intraventricular Hemorrhage/Periventricular Leukomalacia | Increased neonatal encephalopathy in term neonates. No difference or decreased incidence of IVH and PVL in preterm infants Neuroprotective effect of Magnesium Sulfate |

de Souza Rugolo L et. al. PE: Effect on the Fetus and Newborn. *Neoreviews*. 2011;12(4):e198-e206.

From the table above it is showed that the effects of PE on neonatal outcome also includes respiratory system which is respiratory distress syndrome. Furthermore, late preterm infants have greater risk for various complications, mainly respiratory problems. Several studies showed that late-preterm infants have greater risk for respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), persistent pulmonary hypertension (PPHN), and respiratory failure compared to term infants ^{22,26}. The most recent cohort study showed that having pre-eclamptic mother is independently associated with higher risk for severe RDS and Bronchopulmonary Dysplasia (BPD) ²⁷.

Respiratory Distress Syndrome

Respiratory Distress Syndrome or Hyalin Membran Disease is one of the leading causes of death among premature newborns ²⁸. It affects 1% of all newborn infants and about 10% of preterm babies in the United States each year. The syndrome is mainly due to immaturity of lungs in producing surfactant which affects lungs' ability to support respiration ²⁸.

In the context of PE, there's a theory that PE may cause acceleration in fetal lung maturity because it may escalate cortisol production via chronic stress condition caused by PE. In this logic, the increasing production of cortisol should reduce the risk of

experiencing RDS ¹⁰, the data regarding this matter have been contradictory so far.

RDS incidence was found lower among preterm infants less than 34 weeks from hypertensive mothers compared to the control ²⁹. The same results were also found in late preterm infants according to a large population study in the Netherlands ³⁰.

Nevertheless, other studies showed different results. Large cohort studies revealed that preterm infants from mothers with PE especially with gestational age less than 32 weeks have higher risk of RDS ²⁸. Another study which monitored lung maturity of late preterm infants by measuring lecithin - sphingomyelin ratios which later underwent elective deliveries, those infants were still at risk of RDS because almost 10% of them developed RDS. Those studies suggested that PE may not accelerate lung maturity ³¹.

Despite of conflicting results of those studies, neonatologists should be prepared to provide respiratory support to newborns with hypertensive mothers. Early termination of pregnancy due to PE will lead to smaller gestational age. Smaller gestational age is likely to have any respiratory distress, significant physiologic derangement, or experiencing assisted ventilation. Babies born at 37 weeks were twice as likely to be ventilated, whereas

babies born at 36 weeks were five times as likely, and babies born at 35 weeks, nine times as likely compared with babies with gestational ages of 38 to 40 weeks ³². In addition, Wang ML et al found that late-preterm infants have a nine times greater incidence of respiratory distress syndrome than term infants (28.9% versus 4.2%, $P < .001$).³³

Bronchopulmonary Dysplasia

One of chronic lung disease in infancy is bronchopulmonary dysplasia (BPD) that usually occurs in infants born prematurely ³⁴. This also often seen among newborns from mothers with preeclampsia. Several studies examined the relationship between intrauterine exposure to maternal PE and the risk of the infant developing BPD. Some of these report that PE is protective and reduces the incidence of BPD ^{35, 36, 37}. Others report that PE is associated with an increased incidence of BPD ^{38, 39}. Still others have found no change ^{40,41}. A study reported that infants born from PE mothers were more likely to develop BPD compared to infants born from mothers with other causes of preterm delivery. They found that PE increased the likelihood of developing BPD with almost 3-fold (Bivariate OR= 2.96 95% CI = 1.17 to 7.51; $P = .01$). Since BPD has several other risk factors, in this study, the logistic model of other BPD risk factors showed that PE had highest OR (OR: 18.7 CI: 2.44-144.76 $P .005$) ³⁸. However, another study showed contradictory result

that BPD was not associated to PE exposure either before and after adjustment for relevant variables (OR 0.73; 95% CI 0.05, 1.06 and OR 1.14; 95% CI 0.71, 1.81). They concluded that PE exposure had insignificant effect on the risk of developing BPD ⁴².

BPD itself is due to impaired lung growth following early lung injury. It shows the effects of persistent distal lung structure abnormalities including a decrease in alveolarization and pulmonary vascular bed malformations ^{34,43}. In normal lung development, angiogenesis is important process for alveolarization and disruption of pulmonary circulation development plays role in lung hypoplasia ⁴⁴. However, angiogenic and antiangiogenic factors imbalance was considered to be a cause of normal placental angiogenesis disruption in PE and also a cause of abnormal fetal angiogenesis which included vasculature of the fetal lung ³⁹.

Intrauterine vascular growth plays role in pulmonary alveolarization. Greater levels of a Vascular Endothelial Growth Factor (VEGF) antagonist that is soluble VEGF receptor-1 (soluble VEGFR1, also known as soluble fms-like tyrosine kinase 1, sFlt- 1) had been found in pregnant women with PE. There might be an antiangiogenic state in PE that gave a suggestion that newborn from PE mothers had greater risk of developing BPD due to impaired fetal angiogenesis, included impaired lung

development^{38,45}. A study found that preterm infants with BPD have lower concentration of VEGF in tracheal aspirates⁴⁶ and higher concentration of anti angiogenic growth factors, endostatin, in cord blood compared those who do not develop BPD⁴⁷.


Impairment of VEGF signaling in utero can cause disruption of lung development and in addition can increase the risk of BPD. An experimental study conducted in rats revealed this mechanism. After intra-amniotic infusion of sFlt-1, there were a decrease in both pulmonary alveoli and vessel number and an increase in fetal pulmonary endothelial and mesenchymal cells apoptosis. So, there was a suggestion that fetal exposure to greater levels of intra-amniotic sFlt-1 can cause increased risk for BPD and vascular dysfunction in infants from PE mothers⁴⁵.

PE, BPD, and Oxidative Stress

Newborns from mothers with PE are prone to be exposed with oxidative stress. PE is associated with the release of free radicals produced by placenta. This could be the result of persistent hypoxia or intermittent perfusion due to poor placentation. Immune and genetic factors are responsible for poor placentation.¹⁰

Oxidative stress is one of the causes of BPD from mothers who have PE. Oxidative stress could be

also originated from resuscitation and mechanical ventilation. Newborns with asphyxia are prone to have high exposure of oxygen which may lead to oxidative stress⁴⁸. A systematic review study which compared ambient air with 100% oxygen given to depressed preterm and term infants showed significant decrease in neonatal mortality and faster recovery among those who were resuscitated with ambient air ⁴⁹.



The deficiency of enzymatic and non-enzymatic antioxidant could also become the factor of cell/tissue injury caused by oxidative stress. However, studies regarding supplementation of antioxidant agents to prevent oxidative stress haven't resulted encouraging outcome ⁴⁸.

Figure 4. Factors that increase susceptibility of preterm infants to free radical-mediated diseases

Trindade C et al. Free Radicals and Neonatal Diseases. *Neoreviews*. 2007;8(12):e522-e532.

Conclusion

Neonatal Respiratory Outcome in Pregnancy-Induced Hypertension especially in PE has less favorable outcome although there are evidences oppose this view. However, although the pathophysiology still unclear until today, attention should always be given to newborns from mothers with PE. The theory that states mother with PE have lower risk to have newborns with RDS is still a controversy. The newest research regarding BPD also have contradictory results. Newborns from mothers with PE still at risk of suffering poor respiratory outcome such as RDS and BPD. Proper resuscitation and intervention should be prepared in this matter. Oxygen therapy should be given wisely to prevent the adverse effects of free radicals. Multidisciplinary

cooperation is important to provide quality care to newborns from mothers with PE.

References

1. WHO. WHO recommendations for prevention and treatment of PE and eclampsia. Geneva: WHO Press; 2011: 4-5.
2. Rivera-Romero O, Olmo A, Muñoz R, Stiefel P, Miranda M, Beltrán L. Mobile health solutions for hypertensive disorders in pregnancy: Scoping Literature Review. *JMIR mHealth and uHealth*. 2018;6(5):e130.
3. Sirait AM. Prevalensi hipertensi pada kehamilan di Indonesia dan berbagai faktor yang berhubungan (Riset Kesehatan Dasar 2007). Indonesian. Buletin penelitian sistem kesehatan. 2012;15(2):103-9.
4. Kattah A, Garovic V. The Management of hypertension in pregnancy. *Adv Chronic Kidney Dis*. 2013;20(3):229-39.
5. Cruz M, Gao W, Hibbard J. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. *Am J Obstet Gynecol*. 2011;205(3):260.e1-260.e9.
6. Tachiweyika E, Gombe N, Shambira G, Chadambuka A, Tshimamga M, Zizhou S. Determinants of perinatal mortality in Marondera district, Mashonaland East

- Province of Zimbabwe, 2009: a case control study. *Pan Afr Med J.* 2011;8(1):7.
7. Endeshaw G, Berhan Y. Perinatal outcome in women with hypertensive disorders of pregnancy: A retrospective cohort study. *Int Sch Res Notices.* 2015;2015:1-8.
 8. Report of National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol.* 2000;183:S1-S22
 9. Roberts CL, Algert CS, Morris JM, Ford JB, Henderson-Smart DJ. Hypertensive disorders in pregnancy: a population based study. *Med J Aust.* 2005;182:332-5
 10. de Souza Rugolo L, Bentlin M, Trindade C. PE: Effect on the fetus and newborn. *NeoReviews.* 2011;12(4):e198-e206.
 11. Rui-qiong MA, Min-na S, Zi Y. Effects of preeclampsia-like symptoms at early gestational stage on feto-placental outcomes in a mouse model. *Chin Med J.* 2010;123:707-12
 12. Chamy VM, Lepe J, Catalan A, Retamal D, Escobar JA, Madrid EM. Oxidative stress is closely related to clinical severity of pre-eclampsia. *Biol Res.* 2006;39:229-36
 13. Kaur G, Mishra S, Sehgal A, Prasad R. Alterations in lipid peroxidation and antioxidant status in pregnancy with

preeclampsia. *Mol Cell Biochem.*
2008;313:37-44

14. Boutet M, Roland L, Thomas N, Bilodeau JF. Specific systemic antioxidant response to preeclampsia in late pregnancy: the study of intracellular glutathione peroxidases in maternal and fetal blood. *Am J Obstet Gynecol.* 2009;200:530.e1-530.e7
15. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. *J Matern Fetal Neonatal Med.* 2008;21:9-23
16. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. *Hypertens Res.* 2010;33: 561-7
17. Sibai B, Dekker G, Kupferminc M. Preeclampsia. *Lancet.* 2005;365(9461):785-799.
18. Goyal R, Yellon SM, Longo LD, Mata-Greenwood E. Placental gene expression in a rat "model" of placental insufficiency. *Placenta.* 2010;31:568-75
19. Suppo de Souza Rugolo L, Bentlin M, Petean Trindade C. PE. *NeoReviews.* 2012;13(9):e532-41.

20. American College of Obstetricians and Gynecologists Practice Bulletin. Diagnosis and management of PE and eclampsia. *Obstet & Gynecol*; 2002;9:159-67,
21. Sibai B. Preeclampsia as a cause of preterm and late preterm (Near-Term) births. *Semin Perinatol*. 2006;30(1):16-9.
22. Backes C, Markham K, Moorehead P, Cordero L, Nankervis C, Giannone P. Maternal preeclampsia and neonatal outcomes. *J Pregnancy*. 2011;2011:1-7.
23. Haddad B, Sibai BM. Expectant management in pregnancies with severe pre-eclampsia. *Semin Perinatol*. 2009;33:143-51
24. Hauth JC, Ewell MG, Levine RJ, et al: Pregnancy outcome in healthy nulliparous women who subsequently developed hypertension. *Obstet Gynecol*. 2000; 95:24-8,
25. Hnat MD, Sibai B, Caritis S, et al. for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units: Perinatal outcome in women with recurrent PE compared with women who develop PE as nulliparas. *Am J Obstet Gynecol*. 2002;186:422-6,
26. Jain L. Respiratory morbidity in late-preterm infants: prevention is better than cure!. *Am J Perinatol*. 2008;25(02):075-8.
27. Tagliaferro T, Jain D, Vanbuskirk S, Bancalari E, Claire N. Maternal PE and respiratory

- outcomes in extremely premature infants. *Pediatr Res.* 2019;85(5):693-6.
28. Schraufnagel D. Breathing in America. Respiratory distress syndrome of newborns. *Ashland: American Thoracic Society;* 2014;19:197-206.
 29. Shah, Dinesh M. et al. "Neonatal outcome of premature infants of mothers with PE." *J Perinatol.* 1995;15 4:264-7 .
 30. Langenveld J, Ravelli A, van Kaam A, van der Ham D, van Pampus M, Porath M et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation. *Obstet Anesth Digest.* 2012;32(4):216-7.
 31. Lewis D, McCann J, Wang Y, Cormier C, Groome L. Hospitalized late preterm mild preeclamptic patients with mature lung testing: what are the risks of delivery?. *J Perinatol.* 2009;29(6):413-5.
 32. Escobar GJ, Clark RH, Greene JD. Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions. *Semin perinatal.* 2006;30:28-33
 33. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. *Pediatrics.* 2004;114(2):372-6.
 34. Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease:


- bronchopulmonary dysplasia. *N Engl J Med.* 1967;276(7):357-68.
35. Kim CR, Vohr BR, Oh W. Effects of maternal hypertension in very-lowbirth-weight infants. *Arch Pediatr Adolesc Med.* 1996;150:686-91.
36. Korhonen P, Tammela O, Koivisto AM, Laippala P, Ikonen S. Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. *Early Hum Dev.* 1999;54:245-58.
37. Wolf EJ, Vintzileos AM, Rosenkrantz TS, Rodis JF, Salafa CM, Pezzullo JG. Do survival and morbidity of very-low-birth-weight infants vary according to the primary pregnancy complication that results in preterm delivery? *Am J Obstet Gynecol* 1993;169:1233-9
38. Hansen A, Barnés C, Folkman J, McElrath T. Maternal PE predicts the development of bronchopulmonary dysplasia. *J. Pediatr.* 2010;156(4):532-6.
39. Bose C, Van Marter LJ, Laughon M, O'Shea TM, Allred EN, Karna P, Ehrenkranz RA, Boggess K, Leviton A. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. *Pediatrics.* 2009;124(3):e450-8.
40. Akram Khan M, Kuzma-O'Reilly B, Brodsky NL, Bhandari V. Site-specific characteristics of infants developing bronchopulmonary dysplasia. *J Perinatol.* 2006;26:428-35.
41. Redline RW, Wilson-Costello D, Hack M. Placental and other perinatal

- risk factors for chronic lung disease in very low birth weight infants. *Pediatr Res.* 2002;52:713-9.
42. O'Shea J, Davis P, Doyle L. Maternal PE and risk of bronchopulmonary dysplasia in preterm infants. *Pediatr Res.* 2011;71(2):210-4.
 43. Coalson J. Pathology of new bronchopulmonary dysplasia. *Semin Neonatol.* 2003;8(1):73-81.
 44. Abman SH. Bronchopulmonary Dysplasia: "A vascular hypothesis". *Am J Respir Crit Care Med.* 2001;164(10):1755-6.
 45. Tang J, Karumanchi S, Seedorf G, Markham N, Abman S. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking PE with bronchopulmonary dysplasia. *Am J Physiol Lung Cell Mol Physiol.* 2012;302(1):L36-46.
 46. Lassus P, Ristimaki A, Ylikorkala O, Viinikka L, Andersson S. Endothelial growth factor in human preterm lung. *Am J Respir Crit Care Med.* 1999;159:1429-33
 47. Janer J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. *Pediatrics.* 2009;123:1142-6.
 48. Trindade C, Rugolo L. Free radicals and neonatal diseases. *NeoReviews.* 2007;8(12):e522-32.
 49. Tan A, Schulze A, O'Donnell C, Davis P. Air versus oxygen for resuscitation of infants at birth. *Evid Based Child Health.* 2006;1(1):331-50

Di Indonesia, berdasarkan hasil evaluasi MDGs, tingkat kasus kematian ibu (AKI) dan bayi baru lahir (AKB) masih tergolong tinggi. Padahal target yang dicanangkan PBB dalam era SDGs saat ini yaitu 70/100.000 (AKI) dan 23/1.000 (AKB) kelahiran hidup.

Salah satu penyebab masih tingginya AKI-AKB adalah karena belum maksimalnya kualitas pelayanan kesehatan maternal-neonatal di berbagai tatanan fasilitas kesehatan terutama dalam penanganan kasus ibu hamil dengan pre-eklampsia serta dampak pada bayi yang dilahirkannya. Sehingga kita memerlukan rangkaian upaya strategi khususnya dalam usaha peningkatan kualitas pelayanan perinatal dengan memfasilitasi para profesional medis di bidang kesehatan ibu hamil serta bayi baru lahir, terutama para dokter spesialis kandungan, spesialis anak, dokter umum serta bidan dan perawat, untuk senantiasa meningkatkan kapabilitas profesionalitasnya dalam menurunkan angka kematian ibu-bayi dengan tanpa melupakan agar tetap menjaga kualitas luaran dari generasi bangsa dalam perspektif ilmu tumbuh kembang dan rehabilitasi medik.

Buku ini diterbitkan sebagai bahan referensi dalam proses pembelajaran demi majunya pelayanan kesehatan perinatal di tempat sejawat masing-masing bekerja, buku ini berisikan materi-materi topik yang disajikan dalam temu ilmiah yang telah berlangsung. Selamat membaca dan semoga bermanfaat bagi sejawat sekalian.



SAGA

Jl. Kedinding Lor. Gg. Delima no.4A
Kenjeran, Surabaya
saga.penerbit@gmail.com
www.pustakasaga.id

